A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.

Khoo SH, FitzGerald R, Edwards CJ, Ahmad S, Saunders G, Else LJ, Shaw V, Mozgunov P, Northey J, Dickinson L, Knox E, Buadi A, Hale C, Reynolds HE, Middleton C, Bullock K, Walker L, Tetlow M, Lyon R, Gibney J, Amara A, Greenhalf W, Burdon A, Dixon J, Jaki T, Chiong J, Lalloo DG, Owen A, Jacobs M, Fletcher T, Griffiths G, AGILE CST-8 study group

Open source

DOI: 10.1093/jac/dkag180
Published: 2026 Jun 3
Container: The Journal of antimicrobial chemotherapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/jac/dkag180,
  title = {A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.},
  author = {Khoo SH and FitzGerald R and Edwards CJ and Ahmad S and Saunders G and Else LJ and Shaw V and Mozgunov P and Northey J and Dickinson L and Knox E and Buadi A and Hale C and Reynolds HE and Middleton C and Bullock K and Walker L and Tetlow M and Lyon R and Gibney J and Amara A and Greenhalf W and Burdon A and Dixon J and Jaki T and Chiong J and Lalloo DG and Owen A and Jacobs M and Fletcher T and Griffiths G and AGILE CST-8 study group},
  year = {2026},
  journal = {The Journal of antimicrobial chemotherapy},
  doi = {10.1093/jac/dkag180},
  url = {https://doi.org/10.1093/jac/dkag180}
}

RIS

TY  - JOUR
TI  - A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.
AU  - Khoo SH
AU  - FitzGerald R
AU  - Edwards CJ
AU  - Ahmad S
AU  - Saunders G
AU  - Else LJ
AU  - Shaw V
AU  - Mozgunov P
AU  - Northey J
AU  - Dickinson L
AU  - Knox E
AU  - Buadi A
AU  - Hale C
AU  - Reynolds HE
AU  - Middleton C
AU  - Bullock K
AU  - Walker L
AU  - Tetlow M
AU  - Lyon R
AU  - Gibney J
AU  - Amara A
AU  - Greenhalf W
AU  - Burdon A
AU  - Dixon J
AU  - Jaki T
AU  - Chiong J
AU  - Lalloo DG
AU  - Owen A
AU  - Jacobs M
AU  - Fletcher T
AU  - Griffiths G
AU  - AGILE CST-8 study group
PY  - 2026
JO  - The Journal of antimicrobial chemotherapy
DO  - 10.1093/jac/dkag180
UR  - https://doi.org/10.1093/jac/dkag180
ER  -

APA

SH, K., R, F., CJ, E., S, A., G, S., LJ, E., V, S., P, M., J, N., L, D., E, K., A, B., C, H., HE, R., C, M., K, B., L, W., M, T., R, L., J, G., A, A., W, G., A, B., J, D., T, J., J, C., DG, L., A, O., M, J., T, F., G, G., & group, A. C. S. (2026). A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.. The Journal of antimicrobial chemotherapy. https://doi.org/10.1093/jac/dkag180

Source records

pubmed · retrieved 2026-09-26T17:48:32.434Z